Manufacturing Vaccines in Adherent Cell Lines Using Disposable Multi-tray Bioreactors - By allowing a single system to be used from laboratory- to commercial-scale, multi-tray bioreactors can facilita


Manufacturing Vaccines in Adherent Cell Lines Using Disposable Multi-tray Bioreactors
By allowing a single system to be used from laboratory- to commercial-scale, multi-tray bioreactors can facilitate scale up and accelerate vaccine development.

BioPharm International

Table 2. Analysis of N-glycan structures. The majority of N-glycan structures detected after desialylation were complex-type biantennary structures without terminal Gal (36.6%), with one terminal Gal (44.9%) and with two terminal Gal (15.1%). Approximately 2% of the N-glycan structures were still sialylated. This analysis shows that transiently transfected HEK293 cells have the ability to synthesize N-glycan structures similar to those obtained from CHO cells.
After a highly purified product was obtained, the glycosylation patterns were analyzed by looking at N-glycan structures released from the antibodies (Table 2). This analysis confirmed the ability of the transiently transfected HEK293 cells to synthesize N-glycan structures similar to those obtained after stable expression (e.g., in CHO cells). This study showed that the antibodies produced in serum-free conditions using a multi-tray bioreactor were of equal quality to antibodies produced in suspension CHO cells.

IQ Therapeutics BV

In a third study, IQ Therapeutics BV, a Dutch biotechnology company engaged in discovering and developing antibodies for therapeutic use in infectious diseases and for biodefense, uses multi-tray bioreactors (Nunc Cell Factory, Thermo Fisher Scientific) to quickly generate sufficient volumes of antibody material for animal studies. IQ has two monoclonal antibodies for anthrax in preclinical studies. The two antibodies are directed against two components of anthrax's lethal toxin: The antibody IQNPA is directed against protective antigen, and IQNLF is directed against lethal factor. Currently, IQ uses multi-tray bioreactors to produce these antibodies for preclinical studies in animal models. Production for clinical trials, however, is outsourced to a contract manufacturing operation to ensure compliance with current good manufacturing practices.

For in-house production using human hybridomas, IQ began to use multi-tray units instead of standard flasks. After investing some time to optimize the use of the multi-tray bioreactors, IQ researchers found conditions in which IQNPA antibody production improved by more than 30% and IQNLF antibody production more than doubled (+120%), compared to 175-cm2 flasks.

The team at IQ found the system effective and easy to use. "The ten tray cell culture system is very effective in manufacturing 75 mg batches of antibody," said Herman Groen, PhD, the CSO of IQ Therapeutics. "That is sufficient material to do a lot of in vitro functional studies, as well as work in animal models." Hans Westra, responsible for manufacturing at IQ, notes that his team also benefited from simplified protocols when dealing with this type of technology. "The very short time we needed to become accustomed to handling the multi-tray bioreactors made the adaptation of the production process into our facility very easy," he said.

On the Horizon

The evolution of the multi-tray cell culture system for adherent cell line production was enabled by improving upon an existing device, the 175-cm2 flask. The need to scale up adherent cell propagation pushed researchers and engineers to improve upon this technology to create the multi-tray format. The future success of this type of format, however, will be contingent upon continuous innovation and improvement. For example, the application of various surface treatments will help cells adhere to the inner walls of a tray in a stronger and more specific manner. Also, developing multi-tray bioreactors as completely closed systems with customized tubing configurations to facilitate and control the flow of liquids and gases within the interior environment is under way. A closed system like this would provide sterility, flexibility, and speed for vaccine development and production.

Edwin Schwander is the market development manager at Thermo Fisher Scientific, Roskilde, Denmark, +31.6.51541921,

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here